Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cencora (DE:ABG)
BERLIN:ABG
Cencora (ABG) Stock Price & Analysis
1 Followers
ABG Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€147.78 - €225.20
Previous Close€209
Volume0.00
Average Volume (3M)N/A
Market Cap
€42.67B
Enterprise Value€43.67B
Total Cash (Recent Filing)$2.87B
Total Debt (Recent Filing)$4.78B
Price to Earnings (P/E)N/A
Beta0.14
Next Earnings
Jul 31, 2024EPS Estimate
€3.01Next Dividend Ex-Date
May 09, 2024Dividend Yield0.89%
Share Statistics
EPS (TTM)N/A
Shares Outstanding199,451,791
10 Day Avg. Volume1
30 Day Avg. VolumeN/A
Standard Deviation0.09
R-Squared0.06
Alpha-0.00144
Financial Highlights & Ratios
Price to Book (P/B)-3.48
Price to Sales (P/S)0.25
Price to Cash Flow (P/CF)12.90
P/FCF Ratio14.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.16
Enterprise Value/Gross Profit4.87
Enterprise Value/Ebitda16.15
Forecast
1Y Price Target
€242.88Price Target Upside16.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Cencora News
PremiumCompany Announcements
Cencora EVP Gina K. Clark Announces Amicable Retirement
PremiumCompany Announcements
Cencora Schedules Fiscal Quarter Results Discussion Webcast
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCOR's strong financial performance is evident as they surpass 2Q24 EPS expectations and raise the lower end of their future EPS guidance.
Leadership TransitionWith CEO Steve Collis at the helm, COR's shares have significantly outperformed the S&P 500, and the appointment of industry veteran Bob Mauch as the new CEO is expected to continue the company's growth trajectory.
Market Position And StrategyCencora's reaffirmation of its FY24 guidance demonstrates the company's confidence in its financial projections and ongoing strategy to benefit from specialty growth within the pharmaceutical wholesale market.
Bears Say
Cash FlowNet Cash from Operations was down significantly and below estimates.
ProfitabilityThe 12% non-COVID EBIT growth rate cited is not comparable to the 8% growth rate, as the latter does not remove the headwind from lower exclusive COVID vaccines.
Revenue GrowthSlower revenue growth in U.S. Healthcare will likely be an area of focus.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
3.65% Other Institutional Investors
96.35% Public Companies and
Individual Investors
ABG FAQ
What was Cencora’s price range in the past 12 months?
Cencora lowest stock price was €147.78 and its highest was €225.20 in the past 12 months.
What is Cencora’s market cap?
Currently, no data Available
When is Cencora’s upcoming earnings report date?
Cencora’s upcoming earnings report date is Jul 31, 2024 which is in 88 days.
How were Cencora’s earnings last quarter?
Cencora released its earnings results on May 01, 2024. The company reported €3.546 earnings per share for the quarter, beating the consensus estimate of €3.447 by €0.099.
Is Cencora overvalued?
According to Wall Street analysts Cencora’s price is currently Undervalued.
Does Cencora pay dividends?
Cencora pays a Quarterly dividend of €0.48 which represents an annual dividend yield of 0.89%. See more information on Cencora dividends here
What is Cencora’s EPS estimate?
Cencora’s EPS estimate is €3.01.
How many shares outstanding does Cencora have?
Currently, no data Available
What happened to Cencora’s price movement after its last earnings report?
Cencora reported an EPS of €3.546 in its last earnings report, beating expectations of €3.447. Following the earnings report the stock price went up 1.137%.
Which hedge fund is a major shareholder of Cencora?
Among the largest hedge funds holding Cencora’s share is Antipodes Partners Ltd. It holds Cencora’s shares valued at 125M.
---
Cencora Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€242.88 (16.21% Upside)
€242.88 (16.21% Upside)
Blogger Sentiment
Bullish
DE:ABG Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $991.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.22%
12-Months-Change
Fundamentals
Return on Equity
271.45%
Trailing 12-Months
Asset Growth
8.68%
Trailing 12-Months
Company Description
Cencora
Cencora, Inc. engages provision of pharmaceutical products and business solutions that improve access
to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical
Distribution Services segment distributes a comprehensive offering of brand-name, specialty brand-name & generic
pharmaceuticals, over-the-counter healthcare products, home healthcare supplies & equipment, outsourced compounded
sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and
health systems, independent & chain retail pharmacies, mail order pharmacies, medical clinics, long-term care & alternate
site pharmacies, and other customers. The Other segment focuses on global commercialization services and animal health and
includes ABCS, World Courier, and MWI. The company was founded in 1947 and is headquartered in Chesterbrook, PA.
---
ABG Company Deck
---
ABG Earnings Call
Q2 2024
0:00 / 0:00
---
ABG Revenue Breakdown
87.62% Human Health
8.52% Alliance Healthcare
1.93% Other Healthcare Solutions
1.92% Animal Health
---
ABG Stock 12 Months Forecast
Average Price Target
€242.88
▲(16.21% Upside)
Technical Analysis
Best Analysts Covering ABG
1 Year
1 Year Success Rate
10/10 ratings generated profit
1 Year Average Return
+21.21%
reiterated a buy rating 7 months ago
Copying Elizabeth Anderson CFA's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +21.21% per trade.
---